Search Results

Corin Group, a pioneer in orthopaedic innovation, announced the successful completion of first cases using the Apollo™ platform and ApolloKnee™ software for robotic-assisted total knee arthroplasty.

Marker Therapeutics, Inc. reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada.

Apollo Therapeutics announces that during December 2023 it completed a second close of its Series C financing, raising an additional $33.5 million and bringing the total raised in this round by the Company during 2023 to $260 million.

ZAP Surgical Systems, Inc. announced that Apollo Hospital in New Delhi, India, completed its first patient treatment using the new ZAP-X® Gyroscopic Radiosurgery® platform.

Barinthus Biotherapeutics plc (NASDAQ: BRNS) today announced topline final data from the APOLLO trial (also known as HPV001), a completed randomized, placebo-controlled Phase 1b/2 dose-ranging trial of VTP-200 in women with low-grade cervical lesions associated with persistent hrHPV infection.

Apollo Therapeutics, a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, announces the close of $226.5 million in a Series C financing led by lead investor Patient Square Capital.

Apollo Medical Holdings, Inc. today announced that effective on January 23, 2024, the Compensation Committee of ApolloMed’s Board of Directors (the “Committee”) granted 85,130 shares of time-based restricted common stock and 65,265 shares of performance-based restricted common stock to Dinesh M. Kumar, M.D., the Company’s newly-hired Chief Medical Officer, under the Apollo Medical Holdings, Inc. Employment Inducement Award Plan (the “Inducement Plan”).

Alzheon, Inc. announced the dosing of the first patient in a long-term extension of the ongoing pivotal APOLLOE4 Phase 3 trial of 265 mg oral tablet of ALZ-801/valiltramiprosate, administered twice daily, in Early AD subjects carrying two copies of the ε4 allele of the apolipoprotein E gene.